Bomba

Sorrento's R&D imayang'ana kwambiri pakuyendetsa luso mu COVID-19, chithandizo cha khansa, kuwongolera ululu komanso matenda a autoimmune.

Mapulogalamu Ofunika Chizindikiro Zowonongeka Phase I Phase II Gawo III/Pivotal Fomu ya FDA
Mapulogalamu a COVID-19  

COVISTIX™ (zachidziwitso) Rapid Antigen Test

*

Kugwiritsa Ntchito Mwadzidzidzi Authorization (EUA) ku Mexico (COFEPRIS), Brazil (ANVISA), ndi CE Yolembedwa ku Europe

COVIMARK™ (zachidziwitso) Rapid Antigen Test

*

Kufunsira kwatumizidwa ku US ndi Canada kwa Authorization Emergency Use (EUA)

Chithunzi cha VIREX (zachidziwitso) Kunyumba Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (mankhwala) Neutralizing Antibody (IV) mu Odwala Opanda Panja ndi Ogona

20%*

FUJOVEE™ (Abivertinib) Odwala COVID-19 mu ICU Odwala

82%*

Kuyesa Kwambiri Kuyembekezera Chilolezo cha FDA

OQORY™ (COVI-MSC) ARDS chifukwa cha COVID-19 ku ICU Odwala

82%*

Kuyesa Kwambiri ku Brazil

Movomereza Choletsa (piritsi pakamwa) Anti-viral

40%*

Katemera wa Omicron mRNA katemera

20%*

Mapulogalamu Ofunika Chizindikiro Zowonongeka Phase I Phase II Gawo III/Pivotal Fomu ya FDA
immunotherapy  

FUJOVEE™ (Abivertinib) Zamgululi

82%*

FUJOVEE™ (Abivertinib) B Ma cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* Mtengo wa SCLC

82%*

*Mumgwirizano ndi Lee's Pharm ku China

PD-L1 (STI-3031)** Cancer khomo lachiberekero

82%*

**Ku US komanso mogwirizana ndi ImmuneOncia ku Korea

CD47 Zotupa Zolimba

40%*

CD38 DAR-T angapo Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ndi esophageal

40%*

Seprehvec™ oncolytic virus Zotupa Zolimba; Zotupa za CNS

40%*

BCMA ADC Zotupa Zamadzimadzi

20%*

Bevacizumab-ADAB™ Khansa ya Endometrial

40%*

Mogwirizana ndi Mayo Clinic

Bevacizumab-ADAB™ Katemera wa ovarian

40%*

Mogwirizana ndi Mayo Clinic

Rituximab-ADAB™ B-cell Lymphomas

40%*

Mogwirizana ndi Mayo Clinic

Sofusa® anti-PD-1 Matenda a T-Cell Lymphoma (CTCL), Melanoma

40%*

Mapulogalamu Ofunika Chizindikiro Zowonongeka Phase I Phase II Gawo III/Pivotal Fomu ya FDA
ululu  

ZTlido® 1.8%
Postherpetic Neuralgia - PHN

99.8%*

Gloperba®
Chithandizo cha Gout (Oral)

99.8%*

SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain

82%*

SP-103 (Lidocaine Topical System 5.4%) Ululu Wopweteka Kwambiri

60.2%*

SP-104 (Kuchedwa Kuphulika Mlingo Wochepa Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural jakisoni
Ululu Wosasinthika mu Advanced Cancer

60.3%*

Dzina la ana amasiye

RTX (resiniferatoxin)
Njira ya intra-articular
Kupweteka Kwambiri kwa Knee mpaka Bondo

60.2%*

Mapulogalamu Ofunika Chizindikiro Zowonongeka Phase I Phase II Gawo III/Pivotal Fomu ya FDA
Lymphatic Drug Delivery  

Sofusa® odana ndi TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Matenda a T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

Mogwirizana ndi Mayo Clinic
Mapulogalamu a COVID-19
Mapulogalamu Ofunika (Chizindikiro) Phase
COVISTIX™ (zachidziwitso) FDA EUA
COVIMARK™ (zachidziwitso) FDA EUA
Chithunzi cha VIREX (zachidziwitso) PH III
COVISHIELD™ (mankhwala) PH ndi
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Movomereza Inhibitor (mapiritsi apakamwa) Ph II
Katemera wa Omicron mRNA Zowonongeka
immunotherapy
Mapulogalamu Ofunika (Chizindikiro) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Zowonongeka
FUJOVEE™ (Abivertinib) Zowonongeka
FUJOVEE™ (Abivertinib) Zowonongeka
FUJOVEE™ (Abivertinib) Zowonongeka
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Zotupa Zolimba) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ndi esophageal) Ph I
Seprehvec™ oncolytic virus (Zotupa Zolimba; Zotupa za CNS) PH ndi
BCMA ADC (Zotupa zamadzimadzi) Zowonongeka
Bevacizumab-ADAB™ (Cancer ya Endometrial) Ph I
Bevacizumab-ADAB™ (Cancer ya Ovarian) Ph I
Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
ululu
Mapulogalamu Ofunika (Chizindikiro) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Fomu ya FDA
Gloperba® 1.8% Chithandizo cha Gout (Oral) Fomu ya FDA
SEMEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Kuchedwa Kuphulika Mlingo Wochepa Naltrexone) Zowonongeka
RTX (resiniferatoxin) Epidural jakisoni Ph II
RTX (resiniferatoxin) Njira ya intra-articular Ph II
Kutumiza kwa Lymphatic
Mapulogalamu Ofunika (Chizindikiro) Phase II
Sofusa® odana ndi TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Khansa ya pakhungu) Ph I